This CE activity will highlight novel therapies to slow disease progression in patients with early-stage Alzheimer’s disease (AD), including data presented at the Virtual 13th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Digital Conference 2020. The expert faculty, led by Dr. Richard S. Isaacson, will first delve into the pathophysiology, early and accurate differential diagnosis and disease course of Alzheimer’s disease associated with memory loss and cognitive decline, as well as the role of abnormal protein deposits on increasing disease progression in AD. Next, the faculty will analyze newer clinical trial data, including data presented at CTAD 2020, on the safety, efficacy, and tolerability of novel targeted disease modifying treatments for patients with Alzheimer’s disease. To conclude, the faculty will review the current unmet needs of Alzheimer’s disease patients and how to apply integrated strategies for earlier diagnosis and early intervention in practice. Upon completion of this educational activity, clinicians will gain insight into how to better manage their patients with Alzheimer’s disease while utilizing novel targeted therapeutics.
Neurologists, primary care physicians, hospitalists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals who care for patients with Alzheimer’s disease
- Discuss the updated pathophysiology, early and accurate differential diagnosis, and disease course of AD associated with memory loss and cognitive decline, including the role of abnormal protein deposits on increasing disease progression
- Analyze newer clinical trial data on the safety, efficacy, and tolerability of novel targeted disease modifying treatments for patients with AD, including data presented at CTAD 2020
- Advance clinician knowledge on the current unmet AD patient needs and apply integrated strategies for earlier diagnosis and early intervention
I. The Pathophysiology, Early and Accurate Differential Diagnosis, and Disease Course Associated with Memory Loss and Cognitive Decline in Patients with Alzheimer’s Disease
II. A Clinical Trial Review and Analysis of New and Emerging Therapies for AD, Including the Latest Data presented at CTAD 2020
III. Strategies to Coordinate the Healthcare Team, Patients, and Care Givers Through Education and Shared Decision-Making to Improve Outcomes in Patients with AD
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
Richard S. Isaacson, MD
|Consultant/Advisor: 23andMe, Inc.; Eli Lilly and Company; Neurotrack Technologies, Inc.|
Marc E. Agronin, MD
|Consultant/Advisor: Eli Lilly and Company
Speaker’s Bureau: Allergan
Hollie Hristov, MsN, FNp-c
|Nothing to disclose|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider Number P0491).
This activity has been supported by an independent educational grant from Biogen
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].